January 23, 2017

EDAP to Exclusively Distribute LABORIE's Medical Measurement Systems Urodynamic Products in Japan

LYON, France, Jan. 23, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, announced today that it has signed an exclusive agreement with the Canadian company LABORIE to distribute their urodynamic diagnostic products in Japan, one of the largest global markets for urology.

Jean-François Bachelard, General Manager of EDAP TMS's subsidiary in Japan commented: "This agreement consolidates EDAP's position as leader of the Urodynamic market in Japan. LABORIE's products will complement our lithotripsy range of products being distributed by EDAP in Japan as it will provide our sales force with an expanded urology focused product portfolio. We will continue to capitalize on our well established direct network to leverage its expertise and expand our market presence across the country."

Wilfried Woesthuis, Director of International Sales for LABORIE, added, "We are excited to expand our collaboration with EDAP's team. EDAP is very experienced in the Urodynamic field, the team is highly skilled and motivated to support LABORIE's existing large customer base in Japan. In addition, EDAP will introduce new revolutionary LABORIE products such as T-DOC air charged catheter technology to the market. We are looking forward to our continued fruitful cooperation."

Marc Oczachowski, EDAP TMS Chief Executive Officer, concluded: "We are very pleased with this exclusive partnership with LABORIE which continuously introduces innovative and rapidly adopted devices and tools to markets. With LABORIE leading its specific field of urology diagnosis and EDAP focusing on therapeutic urology solutions, this agreement consolidates EDAP's position as a leader company in the urodynamic market in the Japanese territory."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

About LABORIE

LABORIE was founded in 1967 by a pioneer in urodynamics, Ray Laborie. Since then, LABORIE has expanded into new categories and has established itself as a global leader in urology, urogynecology, colorectal and gastroenterology. LABORIE takes great pride in improving patients' lives through innovations in pelvic and gastrointestinal health. Founded by a visionary, today's team remains committed to developing, designing and distributing next-generation solutions. Working closely with clinicians, universities, and non-profits around the globe, we make a difference worldwide. For more information on LABORIE, please visit http://www.laborie.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of

our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Contact:

Blandine Confort

Investor Relations / Legal Affairs EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

CG CAPITAL

877.889.1972

investorrelations@cg.capital

www.cg.capital

Primary Logo

Source: EDAP TMS SA

News Provided by Acquire Media